Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ruditapes philippinarum polysaccharides (ERPP) are natural polysaccharides enzymatically extracted from the clam *Ruditapes philippinarum*. They have demonstrated anti-colorectal cancer activity by inhibiting cell proliferation, suppressing colony formation, and impairing migratory capacity in HT-29 cells. The primary mechanism of action involves the activation of the mitochondrial apoptosis pathway, characterized by the upregulation of the pro-apoptotic gene Bax and downregulation of the anti-apoptotic gene Bcl-2, leading to cytochrome c release and caspase-3 activation. ERPP also exhibits potent antioxidant capacity by scavenging hydroxyl radicals and decreasing reactive oxygen species levels within tumor cells, thereby augmenting its anticancer efficacy. Furthermore, it attenuates tumor angiogenesis through the downregulation of vascular endothelial growth factor A (Vegfaa) gene expression. These properties suggest its potential as a functional food component or an adjuvant therapy for colorectal cancer management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ruditapes philippinarum polysaccharides.